BUZZ-Sichuan Kelun-Biotech at 4-week high on positive lung cancer trial with Merck

Merck & Co., Inc.

Merck & Co., Inc.

MRK

0.00

** Hong Kong shares of Sichuan Kelun-Biotech Biopharmaceutical 6990.HK jump 10.1% to HK$499.6, their highest level since April 22

** Stock of key shareholder Sichuan Kelun Pharmaceutical 002422.SZ surge 9.8% to 35.57 yuan, highest point since April 17

** Sichuan Kelun-Biotech said on Thursday its experimental treatment combined with partner Merck's MRK.N Keytruda improved progression-free survival in patients with advanced lung cancer, meeting the main goal of a late-stage study

** The trial tested the drug, sacituzumab tirumotecan or sac-TMT, in combination with cancer therapy Keytruda as a first-line treatment for patients with advanced non-small cell lung cancer, against Keytruda alone

** YTD, Hong Kong stock up 20.9%, shares of Shenzhen-listed parent up 19.4%


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.